Table 3 Echocardiography, biomarkers and clinical outcome in all patients and stratified by the presence of RV systolic function
All patients | RV systolic function | P value | ||
|---|---|---|---|---|
n = 74 | Normal n = 45 | Abnormal n = 13 | ||
Echocardiography Left ventricle | ||||
LVEF, % | 62 (53 to 67.5) | 63 (57 to 70) | 54 (50 to 63) | 0.018 |
LVEF <50% | 8 (13.6%) | 4 (10.3%) | 3 (25%) | 0.334 |
LV s’, cm/sec | 6 (5 to 7) | 6 (4.9 to 6.93) | 5 (4.77 to 7.41) | 0.813 |
MAPSE, mm | 10.75 (9 to 12.75) | 11.25 (9.17 to 13.25) | 8.88 (6 to 10.38) | 0.004 |
GLS | −17 (−21 to −15) | −20 (−22 to −16) | −15 (−17 to −10) | 0.022 |
VTI, cm | 18.7 (15.4 to 21.9) | 20.2 (15.7 to 23) | 16 (12.3 to 17.9) | 0.011 |
Right ventricle | ||||
TAPSE, mm | 18 (16 to 22) | 20 (18 to 23) | 15 (13 to 16) | <0.001 |
FAC, % | 46 (39 to 53) | 45 (41 to 54) | 47 (34 to 48) | 0.267 |
RVEDA:LVEDA | 0.53 (0.46 to 0.57) | 0.52 (0.46 to 0.57) | 0.56 (0.53 to 0.64) | 0.050 |
RV FWS | −23 (−27 to −21) | −25 (−30 to −22) | −18 (−23 to −13) | <0.001 |
RV TV s’, cm/sec | 9.8 (8 to 12) | 10 (8 to 12.3) | 9 (6 to 9.4) | 0.018 |
hsTnT max, ng/l | 53 (21 to 127) | 47 (16 to 117) | 85 (52 to 239) | 0.026 |
AMInj | 60 (82%) | 34 (75.6%) | 13 (100%) | 0.055 |
Vasopressor days | 9.5 (5 to 21.25) | 9 (4 to 19) | 17 (6 to 24) | 0.201 |
VIS, μg/kg/min | 4.34 (1.94 to 7.31) | 3.78 (1.31 to 6.94) | 4.36 (1.05 to 7.6) | 0.929 |
Proportion requiring IMV | 69 (93%) | 34 (90%) | 14 (93%) | 1 |
IMV days | 14.5 (6.8 to 25.5) | 14 (6 to 24) | 20 (12 to 28) | 0.204 |
SOFA max | 10 (7.5 to 12) | 9 (7 to 11.5) | 9 (8 to 12) | 0.503 |
ICU LOS | 17 (8 to 27.5) | 18 (8 to 28) | 21 (15 to 27) | 0.526 |
ICU mortality | 14 (19%) | 9 (20%) | 1 (7.7%) | 1 |
30-day mortality | 13 (18%) | 7 (15.6%) | 2 (15.4%) | 1 |